BAYER AG

Aignostics raises $34 million in Series B financing to support new product offerings, US expansion, and pathology foundation model development with Mayo Clinic.

AI and new technologies are crucial for early detection and personalized treatment of breast and gynecological cancers, aiming to improve accessibility and outcomes, especially in resource-limited settings.

Insilico Medicine appoints Carol Satler, M.D., PhD, as VP for Non-oncology Clinical Development, to lead validation of ISM001-055 for idiopathic pulmonary fibrosis and strategic planning for non-oncology assets. Satler, with 20+ years of experience at Pfizer, Sanofi, Bayer, Takeda/Millennium, Puretech Health, and Gilead, aims to accelerate clinical validation and bring transformative therapies to market using AI.

The global MoCoD-A treatment market, valued at USD 25 million in 2022, is projected to reach USD 89.96 million by 2033, driven by advancements in genetic and precision medicine. Key players include BridgeBio Pharma, Origin Biosciences, and Orphatech Pharmaceuticals, with treatments like BBP-871 for MoCoD-A. The market growth emphasizes the need for continued research in rare genetic diseases.

The Menopausal Hot Flashes Market report by DataM Intelligence analyzes market trends, key players (Pfizer Inc, AbbVie Inc., Bayer, etc.), and growth projections through 2024-2031. It highlights advancements in medical technologies and patient-centered care driving market growth, with regions including North America, Europe, Asia Pacific, and more covered. Key developments include Veozah's FDA approval and Elda Health's product launch.

SMART trial results presented at Kidney Week 2024 show semaglutide reduces UACR by -52.1% in nondiabetic CKD patients, with sustained effects post-treatment. No significant Cr-eGFR difference observed, but weight and waist circumference reduced. Study explores semaglutide's potential in kidney and cardiovascular care.

The Otc Medicine Market research report forecasts industry growth (2024-2032), highlighting key players like Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Sanofi SA. It details market drivers, regional insights, and segmentation by type, form, distribution channel, application, target group, and region. The report aids strategic decision-making through SWOT, Porter's Five Forces, and Pestle analyses.

FLOW trial data at ASN Kidney Week 2024 shows semaglutide 1.0 mg (Ozempic) reduces major kidney disease events by 24% in type 2 diabetes and CKD patients, with HR 0.76 (95% CI, 0.66 to 0.88; P = .0003). Semaglutide also lowers all-cause mortality (HR, 0.80; 95% CI, 0.67 to 0.95), cardiovascular death (HR, 0.71; 95% CI, 0.56 to 0.89), and death of undetermined cause (HR, 0.62; 95% CI, 0.42 to 0.91).

Dr. Chen Li, CEO of Hua Medicine, received the 'C.C. Tan Life Science Industrialization Award' for his contributions to biopharmaceutical innovation, including the development of Dorzagliatin, the world's first Glucose Kinesin Activator for diabetes treatment.